Analytical Data
-
Gene name
IL31RA
- Application
-
Alternative Names
Interleukin-31 receptor subunit alpha; IL-31R-alpha; IL-31RA; GLM-R; GLM-R; CRL3
-
Species
Human
-
Source
HEK293
-
Tag
C-Avi;C-hFc
-
Purity
> 90% as determined by SDS-PAGE.
-
Uniprot
Q8NI17
-
Expression Region
A20-E519
-
Molecular Weight
120-170 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Related Products
Protein Description
IL-31RA (Interleukin-31 Receptor A) is a crucial component of the IL-31 signaling pathway, which is implicated in various inflammatory and allergic conditions, particularly in skin diseases such as atopic dermatitis. IL-31, a cytokine produced predominantly by Th2 cells, binds to IL-31RA, initiating a cascade of signaling events that contribute to pruritus (itching), inflammation, and other pathological responses. The receptor's expression is notably observed in epithelial cells, immune cells, and neurons, highlighting its role in mediating the effects of IL-31 in different tissues. Due to its involvement in inflammatory diseases, IL-31RA has emerged as a potential therapeutic target for interventions aimed at alleviating itching and inflammation. Research on recombinant IL-31RA proteins focuses on understanding their structure, function, and interaction with IL-31, enabling the development of targeted therapies that can block this pathway. Additionally, the exploration of IL-31RA as a biomarker for disease severity in atopic conditions could provide further insights into personalized treatment approaches. Overall, the study of IL-31RA recombinant proteins holds promise for advancing our understanding of immune-mediated diseases and improving clinical outcomes for patients suffering from chronic inflammatory conditions.
